Integrating Retatrutide Into a Telehealth Platform: Remote Monitoring, Consent, and Compliance Considerations

Telehealth platforms have been at the forefront of GLP prescribing, and many are now exploring retatrutide as a next-generation offering for patients who have not responded adequately to semaglutide or tirzepatide. The telehealth model creates specific challenges for a retatrutide research program — challenges that are solvable, but that require deliberate design rather than simply adapting the standard GLP workflow.

The IRB framework that authorizes retatrutide administration was designed primarily for in-person clinical research. Adapting it to a telehealth model requires addressing several specific issues:

Informed consent in a remote setting: Federal regulations allow electronic informed consent (eConsent) for research, but the eConsent process must meet the same substantive requirements as in-person consent. The patient must have adequate time to review the document, the opportunity to ask questions, and a clear understanding that participation is voluntary. A checkbox at the end of an onboarding flow does not meet this standard.

Remote monitoring: The monitoring requirements in your IRB protocol must be achievable in a remote setting. This means defining what monitoring can be done via telehealth visit (weight, vital signs reported by the patient, symptom assessment) and what requires in-person assessment (laboratory values, physical examination findings).

Adverse event identification: In a remote setting, adverse event identification depends heavily on patient self-reporting. Your program needs a structured mechanism for patients to report symptoms — a patient portal, a dedicated phone line, or a regular check-in protocol — and a clinical team that is responsive to those reports.

When developing your IRB protocol for a telehealth-based program, work with your IRB and healthcare counsel to address the following:

eConsent platform: Use a validated eConsent platform that documents the consent process — when the patient accessed the document, how long they spent reviewing it, whether they asked questions, and when they signed. This documentation is essential for demonstrating that the consent process was adequate.

Remote monitoring schedule: Define a monitoring schedule that is achievable via telehealth. A reasonable structure might include:

• Baseline telehealth visit: comprehensive intake, consent, baseline measurements
• Monthly telehealth visits during titration: weight, vital signs, symptom assessment, dose escalation decision
• Quarterly telehealth visits during maintenance: weight, vital signs, laboratory review (labs ordered through a local lab and reviewed remotely)

Laboratory monitoring: Define which laboratory values you will monitor, how often, and how patients will get labs drawn. Most telehealth platforms use national lab networks (Quest, LabCorp) that allow patients to get labs drawn locally and have results sent to the clinical team.

Adverse event reporting pathway: Define a clear pathway for patients to report adverse events — and a clear response protocol for the clinical team. A patient who reports a serious adverse event via a patient portal message that sits unread for 48 hours is a compliance failure and a patient safety failure.

Telehealth platforms operating across multiple states face additional complexity for a retatrutide research program. The IRB protocol must be consistent with the medical practice laws of every state in which you are enrolling research subjects. Some states have specific requirements for telehealth prescribing of investigational compounds. Work with healthcare counsel to map the state-specific requirements before you begin enrolling patients in those states.

Telehealth platforms have a structural advantage for retatrutide patient acquisition: they already have large patient bases of GLP users who can be identified as candidates for escalation. A telehealth platform with 10,000 active semaglutide or tirzepatide patients has a built-in pool of potential retatrutide research subjects — patients who are already engaged, already paying, and already motivated to achieve better results.

The transition from a standard GLP program to a retatrutide research program can be positioned as a clinical upgrade for patients who have not achieved their goals — not a separate product, but the next step in their care.

Telehealth platforms typically use direct-to-patient shipping, which creates specific cold chain requirements for retatrutide. The compound must be shipped in validated cold chain packaging that maintains the required temperature range throughout transit. Patients must be instructed on how to handle the shipment upon receipt — specifically, how to verify that cold chain integrity was maintained and what to do if the package appears to have been compromised.

Your shipping protocol should be documented in your IRB protocol and reviewed by your IRB. Direct-to-patient shipping of an investigational compound is a specific operational model that the IRB needs to understand and approve.